Study Supplement: NR for Gulf War Illness

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Gulf War Illness
Nicotinamide Riboside - DietarySupplement
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether a 300 mg dose of Nicotinamide Riboside can increase plasma NAD+ levels in participants with Gulf War Illness.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 10 weeks

10 weeks
Fatigue
Changes in general well-being
Changes in immune biomarker profiles
Changes in lipid profiles
Memory
Memory
Changes in mood
Pain
Changes in plasma NAD+ levels

Trial Safety

Trial Design

2 Treatment Groups

Study Supplement: NR
1 of 2
Control
1 of 2

Active Control

Non-Treatment Group

52 Total Participants · 2 Treatment Groups

Primary Treatment: Study Supplement: NR · Has Placebo Group · N/A

Study Supplement: NR
DietarySupplement
ActiveComparator Group · 1 Intervention: Nicotinamide Riboside · Intervention Types: DietarySupplement
Control
DietarySupplement
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: DietarySupplement

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 10 weeks

Who is running the clinical trial?

Roskamp Institute Inc.Lead Sponsor
5 Previous Clinical Trials
374 Total Patients Enrolled
2 Trials studying Gulf War Illness
128 Patients Enrolled for Gulf War Illness
United States Department of DefenseFED
767 Previous Clinical Trials
202,199 Total Patients Enrolled
11 Trials studying Gulf War Illness
668 Patients Enrolled for Gulf War Illness
Nova Southeastern UniversityOTHER
77 Previous Clinical Trials
10,076 Total Patients Enrolled
4 Trials studying Gulf War Illness
384 Patients Enrolled for Gulf War Illness
Andrew Keegan, MDPrincipal InvestigatorThe Roskamp Institute
1 Previous Clinical Trials
52 Total Patients Enrolled
1 Trials studying Gulf War Illness
52 Patients Enrolled for Gulf War Illness
Nancy Klimas, MDPrincipal InvestigatorNova Southeastern University
3 Previous Clinical Trials
210 Total Patients Enrolled
2 Trials studying Gulf War Illness
40 Patients Enrolled for Gulf War Illness
Laila Abdullah, PhDPrincipal InvestigatorThe Roskamp Institute
2 Previous Clinical Trials
128 Total Patients Enrolled
2 Trials studying Gulf War Illness
128 Patients Enrolled for Gulf War Illness

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You were deployed to the Gulf War between August 1990 and August 1991.
Veteran has symptoms of Chronic Multisymptom Illness (CMI) or Kansas GWI.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.